280 related articles for article (PubMed ID: 26104750)
1. Derivation of genetic biomarkers for cancer risk stratification in Barrett's oesophagus: a prospective cohort study.
Timmer MR; Martinez P; Lau CT; Westra WM; Calpe S; Rygiel AM; Rosmolen WD; Meijer SL; Ten Kate FJ; Dijkgraaf MG; Mallant-Hent RC; Naber AH; van Oijen AH; Baak LC; Scholten P; Böhmer CJ; Fockens P; Maley CC; Graham TA; Bergman JJ; Krishnadath KK
Gut; 2016 Oct; 65(10):1602-10. PubMed ID: 26104750
[TBL] [Abstract][Full Text] [Related]
2. A genomic biomarker-based model for cancer risk stratification of non-dysplastic Barrett's esophagus patients after extended follow up; results from Dutch surveillance cohorts.
Hoefnagel SJM; Mostafavi N; Timmer MR; Lau CT; Meijer SL; Wang KK; Krishnadath KK
PLoS One; 2020; 15(4):e0231419. PubMed ID: 32282835
[TBL] [Abstract][Full Text] [Related]
3. Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study.
Ross-Innes CS; Chettouh H; Achilleos A; Galeano-Dalmau N; Debiram-Beecham I; MacRae S; Fessas P; Walker E; Varghese S; Evan T; Lao-Sirieix PS; O'Donovan M; Malhotra S; Novelli M; Disep B; Kaye PV; Lovat LB; Haidry R; Griffin M; Ragunath K; Bhandari P; Haycock A; Morris D; Attwood S; Dhar A; Rees C; Rutter MD; Ostler R; Aigret B; Sasieni PD; Fitzgerald RC;
Lancet Gastroenterol Hepatol; 2017 Jan; 2(1):23-31. PubMed ID: 28404010
[TBL] [Abstract][Full Text] [Related]
4. Aneuploidy in targeted endoscopic biopsies outperforms other tissue biomarkers in the prediction of histologic progression of Barrett's oesophagus: A multi-centre prospective cohort study.
Hadjinicolaou AV; van Munster SN; Achilleos A; Santiago Garcia J; Killcoyne S; Ragunath K; Bergman JJGHM; Fitzgerald RC; di Pietro M
EBioMedicine; 2020 Jun; 56():102765. PubMed ID: 32460165
[TBL] [Abstract][Full Text] [Related]
5. External validation of a model to determine risk of progression of Barrett's oesophagus to neoplasia.
Kunzmann AT; Thrift AP; Johnston BT; McManus DT; Gavin AT; Turkington RC; Coleman HG
Aliment Pharmacol Ther; 2019 May; 49(10):1274-1281. PubMed ID: 30950101
[TBL] [Abstract][Full Text] [Related]
6. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma.
González MV; Artímez ML; Rodrigo L; López-Larrea C; Menéndez MJ; Alvarez V; Pérez R; Fresno MF; Pérez MJ; Sampedro A; Coto E
J Clin Pathol; 1997 Mar; 50(3):212-7. PubMed ID: 9155671
[TBL] [Abstract][Full Text] [Related]
7. Fluorescence in situ hybridization mapping of esophagectomy specimens from patients with Barrett's esophagus with high-grade dysplasia or adenocarcinoma.
Brankley SM; Fritcher EG; Smyrk TC; Keeney ME; Campion MB; Voss JS; Clayton AC; Wang KK; Lutzke LS; Kipp BR; Halling KC
Hum Pathol; 2012 Feb; 43(2):172-9. PubMed ID: 21820152
[TBL] [Abstract][Full Text] [Related]
8. Large intra- and inter-individual variability of genes expression levels limits potential predictive value of molecular diagnosis of dysplasia in Barrett's esophagus.
Hennig EE; Mikula M; Orlowska J; Jarosz D; Bielasik A; Regula J; Ostrowski J
J Mol Med (Berl); 2008 Feb; 86(2):233-42. PubMed ID: 17952395
[TBL] [Abstract][Full Text] [Related]
9. Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot.
Pilonis ND; Killcoyne S; Tan WK; O'Donovan M; Malhotra S; Tripathi M; Miremadi A; Debiram-Beecham I; Evans T; Phillips R; Morris DL; Vickery C; Harrison J; di Pietro M; Ortiz-Fernandez-Sordo J; Haidry R; Kerridge A; Sasieni PD; Fitzgerald RC
Lancet Oncol; 2022 Feb; 23(2):270-278. PubMed ID: 35030332
[TBL] [Abstract][Full Text] [Related]
10. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
[TBL] [Abstract][Full Text] [Related]
11. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
[TBL] [Abstract][Full Text] [Related]
12. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
13. TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma.
Rossi E; Villanacci V; Bassotti G; Donato F; Festa A; Cengia G; Grisanti S; Cestari R
Histopathology; 2010 Jul; 57(1):81-9. PubMed ID: 20557373
[TBL] [Abstract][Full Text] [Related]
14. Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features.
Sato F; Jin Z; Schulmann K; Wang J; Greenwald BD; Ito T; Kan T; Hamilton JP; Yang J; Paun B; David S; Olaru A; Cheng Y; Mori Y; Abraham JM; Yfantis HG; Wu TT; Fredericksen MB; Wang KK; Canto M; Romero Y; Feng Z; Meltzer SJ
PLoS One; 2008 Apr; 3(4):e1890. PubMed ID: 18382671
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Esophageal Adenocarcinoma Risk Using Somatic Chromosome Alterations in Longitudinal Samples in Barrett's Esophagus.
Li X; Paulson TG; Galipeau PC; Sanchez CA; Liu K; Kuhner MK; Maley CC; Self SG; Vaughan TL; Reid BJ; Blount PL
Cancer Prev Res (Phila); 2015 Sep; 8(9):845-56. PubMed ID: 26130253
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of p53 in Barrett's oesophagus.
Krishnadath KK; van Blankenstein M; Tilanus HW
Eur J Gastroenterol Hepatol; 1995 Jan; 7(1):81-4. PubMed ID: 7866817
[TBL] [Abstract][Full Text] [Related]
17. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.
Reid BJ; Prevo LJ; Galipeau PC; Sanchez CA; Longton G; Levine DS; Blount PL; Rabinovitch PS
Am J Gastroenterol; 2001 Oct; 96(10):2839-48. PubMed ID: 11693316
[TBL] [Abstract][Full Text] [Related]
18. Surveillance in Barrett's esophagus: an audit of practice.
Ajumobi A; Bahjri K; Jackson C; Griffin R
Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
[TBL] [Abstract][Full Text] [Related]
19. Barrett's esophagus surveillance in a prospective Dutch multi-center community-based cohort of 985 patients demonstrates low risk of neoplastic progression.
Klaver E; Bureo Gonzalez A; Mostafavi N; Mallant-Hent R; Duits LC; Baak B; Böhmer CJM; van Oijen AHAM; Naber T; Scholten P; Meijer SL; Bergman JJGHM; Pouw RE;
United European Gastroenterol J; 2021 Oct; 9(8):929-937. PubMed ID: 34228885
[TBL] [Abstract][Full Text] [Related]
20. A predictive Bayesian network that risk stratifies patients undergoing Barrett's surveillance for personalized risk of developing malignancy.
Bradley A; Sami S; N G H; Macleod A; Prasanth M; Zafar M; Hemadasa N; Neagle G; Rosindell I; Apollos J
PLoS One; 2020; 15(10):e0240620. PubMed ID: 33045017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
